Palbociclib plus endocrine therapy does not lower QOL in BIPOC
Click Here to Manage Email Alerts
Palbociclib plus endocrine therapy was not associated with lowered quality of life among Black, indigenous and people of color with HR-positive, HER2-negative advanced breast cancer, according to research presented at ASCO 2021.
“The PALOMA study suggested that palbociclib was able to maintain quality of life using patient-reported outcomes,” Gabrielle Betty Rocque, MD, MSPH, FASCO, associate professor of medicine in the divisions of hematology & oncology and gerontology, geriatrics, & palliative care at the University of Alabama at Birmingham, said during the presentation. “However, limited quality of life data exists from real world settings, particularly for Black, indigenous and people of color receiving palbociclib.”
Rocque and colleagues evaluated data from the POLARIS study, a noninterventional prospective study assessing women with HR-positive, HER2-negative disease. They assessed patients’ responses to a quality of life questionnaire at baseline, monthly for the first 3 months of treatment with palbociclib (Ibrance, Pfizer), and at 6 months and 12 months.
Among the 1,280 patients treated with palbociclib, the investigators included 233 patients in the Black, indigenous and people of color (BIPOC) cohort. Of these patients, 59.2% were Black, 35.2% were Hispanic, 3.4% were American Indian or Alaskan Native and 2.1% were Pacific Islander.
In the BIPOC cohort, 68.2% of patients completed quality of life questionnaires for at least 6 months and 48.1% for at least 12 months.
Within the cohort, 116 patients received palbociclib combined with letrozole/anastrozole, 94 patients received palbociclib plus fulvestrant, 13 patients received palbociclib plus exemestane, and 10 received palbociclib plus an additional treatment. Of these patients, 75.1% received palbociclib as first-line treatment.
Rocque and colleagues found that patients’ quality of life scores were stable during the first 12 months of treatment with palbociclib and were similar to the overall study population.
Patients’ scores for symptoms such nausea and vomiting, pain, insomnia, dyspnea, loss of appetite, constipation and diarrhea were also stable during the first 12 months of treatment with palbociclib.
“This real-world study is one of the first to describe quality of life in Black, indigenous, and people of color with [HR-positive/HER2-negative] advanced breast cancer receiving palbociclib and endocrine therapy,” Rocque said. “Palbociclib with endocrine therapy did not adversely affect quality of life in this patient population, which is consistent with findings from our overall POLARIS study, which included all patients in the study.”
Collapse
Click Here to Manage Email Alerts